Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

opportunities. In addition, by selectively reducing cash pay debt,

Angiotech expects the remaining royalty revenue derived from its

partners BSC and Cook Group Incorporated ("Cook") will be adequate to

service any remaining debt. The various assets, including the royalty

business and API equity stake, owned by Angiotech will also allow

continued exploration of additional financing and strategic

alternatives to potentially further reduce or eliminate remaining

Angiotech debt.

Transaction Description and Plan

- Transaction Process. In late 2007 and early 2008, Angiotech

management and its Board of Directors discussed and reviewed various

financial and strategic alternatives, with the goal of evaluating and

pursuing selected opportunities to reduce debt, mitigate certain

risks and improve shareholder value. As a result of this review,

Angiotech conducted a process, together with its financial and legal

advisors, in which multiple potential investors were contacted to

evaluate an investment in API. Angiotech received and evaluated

multiple proposals over the past several months, and ultimately

concluded negotiations with Ares and New Leaf.

- Formation of API. API has been established as a Delaware corporation,

with principal executive offices in Vancouver, British Columbia.

Immediately prior to the close of the transaction, Angiotech and API

will enter into agreements to transfer to API certain assets and

liabilities of Angiotech, which primarily include the various

operating business assets and product development programs of

Angiotech, and exclude (i) intellectual property and royalty revenue

related to BSC's TAXUS paclitaxel-eluting coronary stent system; (ii)

potential royalty and other income from certain
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
(Date:1/14/2014)... January 14, 2014 Independent publisher Bitingduck ... and Montreal, Canada, has big ideas for 2014 in ... press's goals are to produce high-quality, low-cost, DRM-free ebooks ... local businesses. , The first major development will ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 12 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... and,nine months ended Sept. 30, 2007. Third ... for the third quarter and nine months ended ... respectively, compared with $16.5 million,and $30.2 million, respectively, ...
... Fla., Nov. 12 GeoPharma, Inc. (Nasdaq:,GORX) (the ... an,approval from the FDA to begin producing Carprofen. ... is a,non-steroidal anti-inflammatory drug (NSAID) that is used ... associated with osteoarthritis in,dogs. Additionally, Carprofen is often ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 6GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 2GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 3BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... National University (ANU), have developed a new way ... over the past 5.3 million years., The findings ... ice ages over the past two million years, ... dioxide levels, global temperatures and sea levels., The ... and the National Oceanography Centre (NOC) in the ...
(Date:4/16/2014)... collections two new species of yellow-shouldered bats have been unearthed by ... Museum of Natural History and described in the open access journal ... genus Sturnira are part of a recent discovery of ... one still waiting to be officially announced. , Up until recently ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... and bees may do it, but the microscopic animals called ... thank you. Whats more, they have done so over millions ... These hardy creatures somehow escape the usual drawback of asexuality ... Meselson, and their colleagues are finding out how. ...
... to permanent paralysis and loss of sensation below the site ... The nerve fibers or axons have the capacity to grow ... develops around the injury. Northwestern University researchers have ... of scar tissue at the injury site and enables the ...
... available in French . , Modern ... of the worlds water flows, with potentially sudden and ... them researchers at the Stockholm University-affiliated Stockholm Resilience Centre ... published April 1 in the journal Trends in Ecology ...
Cached Biology News:Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3Promising new nanotechnology for spinal cord injury 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 3
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: